Berlin - Delayed Quote EUR

Akero Therapeutics Inc (0K4.BE)

53.72

-0.02

(-0.04%)

As of 1:55:13 PM GMT+1. Market Open.

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to p

GlobeNewswire 16 hours ago

AKRO
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks 22 hours ago

BIIB

SAGE

AKRO
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks yesterday

SAGE

BIIB

CYTK
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.

Zacks yesterday

AKRO

NVO
BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 2 days ago

BIOA

AKRO

VNDA
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purcha

GlobeNewswire 2 days ago

AKRO
Akero’s cirrhosis treatment shows promise in Phase IIb study

In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.

Clinical Trials Arena 2 days ago

AKRO
Why Akero Therapeutics Inc. (AKRO) Surged on Monday

We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note, with the Dow Jones the sole gainer, […]

Insider Monkey 3 days ago

AKRO

^GSPC
Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.

Investor's Business Daily 3 days ago

AKRO

ETNB
Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. In addition, Akero intends to grant the underwriters a 30-day o

GlobeNewswire 3 days ago

AKRO
Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data

A groundbreaking trial shows Akero's drug can reverse cirrhosis, defying expectations--analysts say the upside could be massive.

GuruFocus.com 3 days ago

AKRO
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.

Investopedia 3 days ago

AKRO
Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal

Akero Therapeutics' stock surged following Phase 2b SYMMETRY study results.

GuruFocus.com 3 days ago

AKRO
Akero Therapeutics Stock Doubles on Liver Data

The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically intended to treat MASH.

Barrons.com 3 days ago

AKRO
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

On Monday, Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH). Among patients with baseline and week 96 biopsies (n=134), 39% of patients treated with 50mg EFX (n=46) experienced reversal of cirrhosis with no

Benzinga 3 days ago

AKRO
Akero says MASH drug reverses liver damage in study, doubling shares

Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

BioPharma Dive 4 days ago

AKRO
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 S

GlobeNewswire 4 days ago

AKRO
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, pl

GlobeNewswire 6 days ago

AKRO
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

-- 601 patients have been enrolled in the double-blind portion of the SYNCHRONY Real-World study since initiation in November 2023 -- -- Data from SYNCHRONY Real-World study anticipated in the first half of 2026 -- SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced it has completed enro

GlobeNewswire 18 days ago

AKRO
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of th

GlobeNewswire 24 days ago

AKRO

Performance Overview

Return	0K4.BE	S&P 500
YTD	+100.15%	+2.78%
1-Year	+160.78%	+23.27%
3-Year	+267.95%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akero Therapeutics Inc (0K4.BE)

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero’s cirrhosis treatment shows promise in Phase IIb study

Why Akero Therapeutics Inc. (AKRO) Surged on Monday

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal

Akero Therapeutics Stock Doubles on Liver Data

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Akero says MASH drug reverses liver damage in study, doubling shares

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview